CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 506 enrolled
Drug / intervention
Lidocaine Hydrochloride +1 moredrug
Likely dose
Lidocaine Hydrochloride 5 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00953199
NCT00953199N/ACompleted

A Single Center, Randomized, Double-Blind Controlled Study of Topical Endoluminal Pancreatic Duct Lidocaine for Prevention of Post-ERCP Pancreatitis

Abraham Mathew MD·interventional·Posted Aug 6, 2009·Updated Oct 3, 2017

In Brief

A clinical study evaluating Lidocaine Hydrochloride and Normal Saline for Pancreatitis. Completed, enrolled 506 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if lidocaine is effective in reducing the incidence of post-ERCP pancreatitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatitis
CountriesUnited States

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 6, 2009
Enrollment StartMar 1, 2010
Primary CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 16.9 years ago

Interventions

Lidocaine Hydrochloridedrug

1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with lidocaine 2% (5 ml) used at ERCP. Lidocaine will only be used once, and thus a maximum dose of 100 mg will be employed. If the patient requires more contrast agent, this will be used without the addition of lidocaine.

Normal Salinedrug

1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) used at ERCP (standard of care).